Alaunos Therapeutics, Inc.
Developing TCR-T cell therapies to treat solid tumors by targeting specific cancer mutations.
TCRT | NDAQ
Overview
Corporate Details
- ISIN(s):
- US98973P1012
- LEI:
- Country:
- United States of America
- Address:
- 501 E LAS OLAS BLVD, 33301 FORT LAUDERDALE
- Website:
- https://alaunos.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Alaunos Therapeutics, Inc. is a clinical-stage cellular immuno-oncology company focused on developing T-cell receptor (TCR-T) cell therapies for the treatment of solid tumors. The company engineers therapies to target neoantigens that arise from specific genomic 'hotspot' mutations in cancer cells. Its approach utilizes the proprietary hunTR® platform, a discovery engine for expanding its TCR library, and the 'Sleeping Beauty' non-viral transposition technology. This manufacturing process is designed to be rapid, flexible, and cost-effective, aiming to deliver tumor-specific T cells to cancer patients with significant unmet clinical needs.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Alaunos Therapeutics, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Alaunos Therapeutics, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Alaunos Therapeutics, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
/other/Diamyd_Medical_AB_publ-logo.png){kind=logo}
